A randomized, open-label study evaluating the effect of peginterferon alfa-2a (40KD) (PEGASYS) or adefovir dipivoxil (ADV) on HBeAg seroconversion in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.

Trial Profile

A randomized, open-label study evaluating the effect of peginterferon alfa-2a (40KD) (PEGASYS) or adefovir dipivoxil (ADV) on HBeAg seroconversion in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Adefovir dipivoxil
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche; Shanghai Roche Pharmaceuticals
  • Most Recent Events

    • 08 Dec 2009 Actual end date (1 Jun 2008) added as reported by ISRCTN: Current Controlled Trials.
    • 08 Dec 2009 New source identified and integrated (ISRCTN: Current Controlled Trials, 79659320).
    • 23 Jul 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top